Clinical stage biopharmaceutical company focusing on development and commercialisation of unique cancer therapeutics, TRACON Pharmaceuticals (NASDAQ:TCON), on 22nd July, 2021 announced that due to demand, underwriter has accepted on augmenting size of earlier announced public offering. TRACON said that purchase on a firm commitment basis 3,926,702 shares of common stock of firm at a price …